JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses.

Catastrophic intra-abdominal thrombosis can result from a variety of prothrombotic states, including polycythemia vera and essential thrombocythemia, both of which are frequently associated with an acquired mutation (V617F) in the JAK2 gene. To assess the prevalence and clinical implications of this mutation in the setting of intra-abdominal thrombosis, JAK2 V617F genotyping was performed in 42 patients who had catastrophic intra-abdominal thromboses resulting in visceral transplants. The prevalence of V617F was compared with that of other prothrombotic states for which molecular testing is routinely performed. V617F mutations were detected in 7 patients (17%), who were not distinguishable on the basis of their peripheral blood cell counts. The median posttransplantation survival of V617F+ patients was 17.5 months, compared with 116.4 months for the V617F- patients (ratio, 6.6; 95% confidence interval, 6.3-7.0). These results highlight the diagnostic usefulness of JAK2 V617F testing in this setting and underscore the clinical significance of a positive result.

[1]  D. Steensma,et al.  Elevated serum erythropoietin levels in patients with Budd‐Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis , 2006, European journal of haematology.

[2]  H. El Housni,et al.  Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant. , 2006, Clinical chemistry.

[3]  P. Heimann,et al.  The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors , 2006, Leukemia.

[4]  T. Greiner.  Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2006, American journal of clinical pathology.

[5]  J. Briere.  Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. , 2006, Seminars in thrombosis and hemostasis.

[6]  G. Mufti,et al.  Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. , 2005, Gastroenterology.

[7]  N. Villamor,et al.  Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. , 2006, Haematologica.

[8]  E. Estey,et al.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. , 2005, Blood.

[9]  T. Barbui,et al.  Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. , 2005, Seminars in hematology.

[10]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[11]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[12]  T. Barbui,et al.  Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. , 2005, Experimental hematology.

[13]  D. Valla,et al.  Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis , 2005, British journal of haematology.

[14]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[15]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[16]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[17]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[18]  H. Heimpel,et al.  Budd-chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases , 1989, Klinische Wochenschrift.

[19]  C. Harrison.  Platelets and thrombosis in myeloproliferative diseases. , 2005, Hematology. American Society of Hematology. Education Program.

[20]  J. García‐Pagán,et al.  Increased CD11b neutrophil expression in Budd–Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera , 2004, British journal of haematology.

[21]  G. Klintmalm,et al.  Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders1 , 2002, Transplantation.

[22]  A. Grigg,et al.  Portal or hepatic vein thrombosis as the first presentation of a myeloproliferative disorder in patients with normal peripheral blood counts. , 2002, Clinical and laboratory haematology.

[23]  T. Starzl,et al.  Intestinal transplantation for patients with short gut syndrome and hypercoagulable states. , 2000, Transplantation proceedings.

[24]  D. Valla,et al.  Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors , 2000, Hepatology.

[25]  T. Barbui,et al.  Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. , 2000, Blood.

[26]  D. Blickstein,et al.  Thrombotic complications in essential thrombocythemia with relatively low platelet counts , 1997, American journal of hematology.

[27]  P. Ridker,et al.  Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. , 1997, JAMA.

[28]  G. Leone,et al.  Spontaneous Erythroid Colony Formation as the Clue to an Underlying Myeloproliferative Disorder in Patients with Budd-Chiari Syndrome or Portal Vein Thrombosis , 1997, Seminars in thrombosis and hemostasis.

[29]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[30]  D. Valla,et al.  Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. , 1988, Gastroenterology.

[31]  D. Valla,et al.  Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. , 1985, Annals of internal medicine.